U.S. Health Secretary Robert F. Kennedy Jr. says the Trump administration wants to establish a regulated marketplace for peptide products, signalling a potentially significant shift in how certain peptides could be accessed and manufactured in the United States.

Speaking during an interview on October 20, Kennedy argued that consumer demand for peptides already exists and is unlikely to disappear. The administration’s objective, he said, is to move the market toward products that are accurately identified, manufactured in inspected facilities and subject to clearer safety and quality controls.

His comments followed reports that the U.S. Food and Drug Administration had submitted a proposed peptide policy change to the White House for review. The proposal could make it easier for compounding pharmacies to prepare certain peptides under appropriate conditions. reuters.com

From a Grey Market to a Regulated System

Interest in peptides has expanded rapidly, driven partly by social-media discussions about their potential applications in pain management, tissue recovery, muscle development, healthy aging and aesthetic care.

However, many of the peptides gaining attention are not FDA-approved drugs. Consumers have frequently obtained them through online vendors and other grey-market channels, where questions may exist about ingredient identity, concentration, contamination, storage and manufacturing standards.

Kennedy’s comments suggest that the administration views regulated access as a possible alternative to leaving that demand in an uncontrolled market.

A regulated system could introduce clearer requirements around manufacturing facilities, product testing, accurate labelling and professional oversight. The exact requirements—and which peptides might qualify—will depend on the language of any policy ultimately adopted.

FDA Proposal Moves to White House Review

According to Reuters, Kennedy was responding to a question about a proposed FDA policy change that had been submitted to the White House for review.

That review represents another step in the federal regulatory process. It does not mean the policy has been finalized, nor does it immediately change the legal status of the peptides being considered.

The proposal follows a July meeting of the FDA’s Pharmacy Compounding Advisory Committee. Outside advisers recommended easing compounding restrictions on six of the seven peptides reviewed, including BPC-157.

Those recommendations were made despite concerns raised by FDA staff about the limited human evidence available for several of the substances. The advisory committee’s recommendations were nonbinding, leaving the final policy decision with the FDA.

Compounding Is Not the Same as FDA Approval

If the proposal moves forward, certain peptides could potentially become more accessible through regulated compounding pharmacies when prescribed for an individual patient.

This would not mean that the peptides had received FDA approval.

FDA-approved drugs undergo a formal review process intended to establish safety, effectiveness, manufacturing consistency and approved conditions of use. Compounded preparations do not pass through that same premarket approval pathway.

Permission to compound a substance therefore should not be interpreted as confirmation that it has been proven safe or effective for a particular medical condition.

The peptides under consideration have not been approved by the FDA as safe and effective drugs. Human evidence remains limited, even where laboratory research, animal studies or patient experiences have generated interest.

Why the Development Matters

The administration’s stated goal reflects an important regulatory question: how should officials respond when public demand develops faster than the conventional clinical evidence?

Leaving the market entirely outside regulated healthcare channels may expose consumers to inaccurately labelled, contaminated or improperly manufactured products. Allowing carefully controlled pharmacy compounding could create stronger standards for sourcing, production and professional oversight.

However, improvements in product quality would not resolve every scientific question. More controlled human research would still be needed to determine appropriate dosing, potential interactions, long-term risks and whether individual peptides produce meaningful clinical benefits.

The proposed policy represents a potentially important change in the federal government’s approach to peptides. For now, it remains under review, and the details of any regulated marketplace—including which substances would be included and what safeguards would apply—have not been finalized.

Original source: Reuters — Kennedy Says Trump Administration Aims for Regulated Market for Peptides, published October 20, 2026.

Editorial note: The proposed policy remains under review. A regulated compounding pathway would not constitute FDA approval or establish that the peptides involved are safe or effective for a particular use.